Zhejiang Tailisen Pharmaceutical

Zhejiang Tailisen Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, and large-scale manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company focuses on several therapeutic areas, including antiviral, cardiovascular, antidiabetic, and antifungal treatments. Key products in its portfolio include Oseltamivir phosphate, Rosuvastatin calcium, and Sitagliptin phosphate. Tailisen operates high-standard manufacturing facilities that comply with global Good Manufacturing Practice (GMP) requirements, serving both domestic and international markets. The company is recognized for its expertise in complex chemical synthesis and high-quality pharmaceutical production. It plays a significant role in the supply chain for essential medications, particularly in the production of antiviral treatments for influenza.